ライフサイエンスコーパス: proguanil

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ren who received IPT than those who received proguanil.

2 f patients took <75% of their daily doses of proguanil.

3 nct from the activity of its parent compound proguanil.

4 eventing malaria than daily prophylaxis with proguanil.

5 , six participants received daily atovaquone-proguanil 1 day before CHMI (cohort 1B), and six partici

6 amodiaquine (2.9%) and artesunate-atovaquone-proguanil (1.0%) groups.

7 lligrams of atovaquone and 400 milligrams of proguanil (1000/400 milligrams) on day -7.

8 n additional group received daily atovaquone-proguanil (250-100 mg) for 9 days, starting 1 day before

9 lligrams of atovaquone and 100 milligrams of proguanil (250/100 milligrams) 1 day prior to infectious

10 lligrams of atovaquone and 200 milligrams of proguanil (500/200 milligrams) on day -7 or, (5) 1000 mi

11 s, as indicated by their hypersensitivity to proguanil, a drug that collapsed the membrane potential

12 To investigate suggestions that WR99210 and proguanil act against a target other than the reductase

13 re prodrugs analogous to the relationship of proguanil and its active metabolite cycloguanil.

14 n only (95 AL, 162 mefloquine, 36 atovaquone-proguanil [AP], and 17 others), and 87 were administered

15 w alternative non-ACTs, including atovaquone-proguanil, are currently available.

16 a-blocker propranolol, the antimalarial drug proguanil, certain antidepressants and barbiturates, and

17 before CHMI and six of six in the atovaquone-proguanil cohort were protected, whereas placebo recipie

18 nt to the synergistic effects of atovaquone/ proguanil combination.

19 were also found for atovaquone, chloroquine, proguanil, cycloguanil and methylene blue.

20 anti-malarial drug used in combination with proguanil (e.g. Malarone(TM)) for the curative and proph

21 iaquine (SPAQ) was more effective than daily proguanil for malaria prevention in subjects with SCD.

22 r Papua New Guinea, in which case atovaquone-proguanil is best, with mefloquine or quinine plus tetra

23 The target of proguanil itself is separate from DHFR.

24 e randomized to receive daily treatment with proguanil or IPT with either MQAS or SPAQ once every 2 m

25 resistance, a combination of atovaquone and proguanil or quinine plus tetracycline or doxycycline or

26 signed to artesunate-amodiaquine, atovaquone-proguanil, or artesunate-atovaquone-proguanil treatment

27 Allocation to DSM265, atovaquone-proguanil, or placebo was randomised by an interactive w

28 Single-dose atovaquone-proguanil provides effective malaria chemoprophylaxis ag

29 terest in the antimalarial drugs WR99210 and proguanil, the cycloguanil precursor.

30 after artesunate-amodiaquine and atovaquone-proguanil therapies, respectively.

31 f susceptibility of transformed parasites to proguanil, thus providing evidence of intrinsic activity

32 rial to establish the efficacy of atovaquone-proguanil to prevent malaria with the goal of simulating

33 However, the proportion of atovaquone-proguanil-treated patients with positive smears on day 3

34 ovaquone-proguanil, or artesunate-atovaquone-proguanil treatment groups and followed for 28 days, acc

35 Artesunate-atovaquone-proguanil was a highly effective alternative treatment.

36 Atovaquone-proguanil was characterized by a slow blood schizontocid

37 Artesunate-atovaquone-proguanil was not associated with any failure.

38 Atovaquone/proguanil was the most commonly prescribed antimalarial

39 fficacy against malaria, compared with daily proguanil, was 61% (95% confidence interval, 3%-84%) for

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。